Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Incidence and predictors of phantom shocks in implantable cardioverter defibrillator recipients.

Kraaier K, Starrenburg AH, Verheggen RM, van der Palen J, Scholten MF.

Neth Heart J. 2013 Apr;21(4):191-5. doi: 10.1007/s12471-012-0345-z.

2.

Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.

Bollmann A, Husser D, Cannom DS.

Am J Cardiovasc Drugs. 2005;5(6):371-8. Review.

PMID:
16259525
3.

Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review.

Gracieux J, Sanders GD, Pokorney SD, Lopes RD, Thomas K, Al-Khatib SM.

Int J Cardiol. 2014 Dec 20;177(3):990-4. doi: 10.1016/j.ijcard.2014.09.170. Epub 2014 Oct 5. Review.

PMID:
25449512
4.

Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches.

Borne RT, Varosy PD, Masoudi FA.

JAMA Intern Med. 2013 May 27;173(10):859-65. doi: 10.1001/jamainternmed.2013.428. Review.

PMID:
23546173
5.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

6.

Association of Implantable Cardioverter Defibrillator Therapy with All-Cause Mortality-A Systematic Review and Meta-Analysis.

Qian Z, Zhang Z, Guo J, Wang Y, Hou X, Feng G, Zou J.

Pacing Clin Electrophysiol. 2016 Jan;39(1):81-8. doi: 10.1111/pace.12766. Epub 2015 Nov 19. Review.

PMID:
26470761

Supplemental Content

Support Center